Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer

https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer

Related Videos

Related Content

Advertisement

April 14th 2025

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

Kyle Munz

Coverage from the Atlanta Regional meeting of the Institute for Value-Based Medicine.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD

This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.

Related Content

Advertisement

April 14th 2025

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

Kyle Munz

Coverage from the Atlanta Regional meeting of the Institute for Value-Based Medicine.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD

This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw

The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.

March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi

With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.